

7:30 8:00 9:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00

Hall Building	Room 1 4F Hall C		9:00~11:00 Symposium 1 Hematopoietic Stem Cell Transplantation in the Era of Cancer Genomics Koichi Akashi, Seishi Ogawa p.3		12:25~12:50 Opening Ceremony	12:50~14:20 Symposium 2 E Symposium for Umbilical Cord Blood Transplantation Shuichi Taniguchi, Satoshi Takahashi p.3	14:30~15:30 Symposium 3 E Haplo-HSCT: Recent changes Naoyuki Uchida p.4		18:30~19:10 Mini Concert						
	Room 2 7F Hall B7 (1)	9:00~10:00 Nursing Oral Session 1 Care Kazue Mori, Hitomi Nishimoto p.91	10:05~11:05 Nursing Educational Lecture 1 Current State of CAR-T Therapy Speakers: Hideki Goto, Hiroko Fukuda Chair: Yuka Okamura p.4	11:20~12:10 LS1 What to consider when using aporinab for B-ALL -Focusing on management of adverse events- Speaker: Hideki Goto Chair: Mamiko Sakata (AbbVie GK/Genmab K.K.)		13:00~14:00 Nursing Educational Lecture 2 Demoralization Speakers: Yu Tamada, Reiko Yasui Chair: Kumiko Takasaka p.4	14:05~15:05 Team Approach 1 Reflecting on Transition Chikako Ohwada, Tomoko Fukuchi p.5	15:10~16:10 Symposium 4 From Transplant Coordination to the Management of Complications during LTFU after Transplantation Takahiro Fukuda (MSD K.K.) p.5	16:25~17:15 SS1 CAR-T cell therapy based on clinical outcome and operation of Kyushu in Japan Speakers: Yasuyuki Arai, Hiroko Fukuda Chair: Tatsu Shimoyama (Novartis Pharma K.K.)					Reception 19:30~21:30	
	Room 3 7F Hall B7 (2)	9:00~11:00 Workshop 1 SOS/TA-TMA Atsushi Kikuta, Hirohisa Nakamae p.6		11:20~12:10 LS2 Evolving infectious disease countermeasures in blood cancer treatment Speaker: Toshihiro Miyamoto Chair: Shuichi Taniguchi (MSD K.K.)		13:00~14:30 Symposium 5 New era infectious disease management Takahiro Fukuda (Asahi Kasei Pharma Corporation) p.6	14:40~16:10 Symposium 6 E Current Status of CAR-T Cell Therapy Koji Izutsu, Go Yamamoto p.7								
	Room 4 5F Hall B5	9:00~10:30 Workshop 2 Rehabilitation + NST Shigeo Fuji, Daisuke Kiguchi p.8		11:20~12:10 LS3 E Umbilical cord blood transplant, management of GVHD Speakers: Kiyon Liu, John E. Wagner Chair: Mine Harada (Chugan Pharmaceutical Co., Ltd.)		13:00~14:30 Workshop 3 Oncologic Cardiovascular Sciences in Transplantation and Cell Therapy Hiroshi Akazawa, Kimikazu Yakushijin p.8	14:40~16:10 Workshop 4 Transplantation in the Elderly Takuro Kuriyama, Hisashi Yamamoto p.9		16:25~17:15 SS2 Treatment Strategies for DLBCL in the Era of Cellular Immunotherapy Speaker: Hideki Goto Chair: Koji Kato (Chugan Pharmaceutical Co., Ltd.)						
	Room 5 7F Hall D7	8:50~9:20 EL1 Speaker: Yoshiyuki Takahashi Chair: Ryoji Kobayashi p.9	9:25~9:55 EL2 Speaker: Yuki Kagoya Chair: Shigeru Chiba p.9	10:00~10:30 EL3 Speaker: Masahiko Makino Chair: Shuichi Mizuta p.9	10:35~11:05 EL4 Speaker: Hideki Araoka Chair: Hikaru Kobayashi p.10	11:20~12:10 LS4 How to collaborate multidisciplinary to accomplish success in CAR-T therapy. Speakers: Nobuharu Fujii, Tomoyo Okawa Chair: Koji Izutsu (Gilead Sciences)	13:00~14:30 JSTCT-KSBMT Joint Symposium E Strategies for recurrence prevention in high-risk transplantation Seong Kyu Park, Takanori Teshima p.10	14:50~15:50 The allied organizations forum for promoting hematopoietic stem cell transplantation p.10	16:25~17:15 SS3 Current and future perspective in Multiple Myeloma Speaker: Shinsuke Iida Chair: Toshihiro Miyamoto (Pfizer Japan Inc.)						
	Room 6 5F Hall D5	9:00~11:00 HCTC Workshop Support for Patients with Post-Transplant Relapse by HCTC Shinichiro Mori, Madoka Narita p.11		11:20~12:10 LS5 Treatment strategies of FLT3-mutated acute myeloid leukemia in real practice Speaker: Aya Nishida Chair: Koichi Akashi (Astellas Pharma Inc.)		13:10~14:10 HCTC Roundtable Recent Related Donor Coordination Namie Yamazaki, Madoka Narita p.11			16:25~17:15 SS4 cGVHD treatment based on cases -Therapeutic significance of J1K inhibition- Speakers: Hisashi Yamamoto, Masaya Numata Chair: Yoshinobu Maeda (Janssen Pharmaceutical K.K.)						
	Room 7 1F Hall D1		9:45~10:57 Oral Session 1 CAR-T 1 Yasushi Sawayama p.25		11:20~12:10 LS6 Treatment strategy for FLT3 mutation-positive acute myeloid leukemia -Including the QUANTUM First trial- Speaker: Masatsugu Tanaka Chair: Takahiro Fukuda (DAICHI SANKYO COMPANY, LIMITED.)		14:40~15:52 Oral Session 3 CAR-T 3 Shuro Yoshida p.28		16:25~17:15 SS5 Real-world data on VEM+AZA therapy in Japanese patients with AML. Speaker: Hiroki Yamaguchi Chair: Koichi Akashi (AbbVie GK)						
	Room 8 4F G402		10:00~11:00 Oral Session 4 Immune Reconstitution /GVL Itaru Kato p.29		11:20~12:10 LS7 The position of human bone marrow-derived mesenchymal stem cell in the treatment of acute GVHD Speaker: Makoto Onizuka Chair: Makoto Murata (UCR Pharmaceuticals Co., Ltd.)		14:20~15:08 Oral Session 6 Pediatric-specific transplant indications 2 Chihaya Imai p.31	15:15~16:03 Oral Session 7 Transplant immunology /chimerism Naoki Kurita p.32	16:25~17:15 SS6 Treatment Option as BCP for 2L cGVHD Speakers: Yasushi Onishi, Hiroko Tsunenome Chair: Tetsuya Nishida (Walincroot Pharmaceuticals)						
	Room 9 4F G409		9:45~10:57 Oral Session 8 Stem cell source 1 Tatsuo Oyake p.33		11:20~12:10 LS8 Current Situation and Prospects of LTFU Speakers: Shingo Sunagawa, Saiko Kurosawa Chair: Takehiko Mori (Novartis Pharma K.K.)		14:40~15:40 Oral Session 10 HCTC/coordination Mari Saigusa p.37		16:25~17:15 SS7 Ph+ ALL treatment strategies in pre- and post-transplant settings Speakers: Satoshi Nishiwaki, Hideki Nakasone Chair: Shingo Yano (Chugan Pharmaceutical Co., Ltd.)						
	Room 10 5F G502		10:00~11:00 Oral Session 11 Graft failure Masahide Yamamoto p.38		11:20~12:10 LS9 The positioning of Inmazumab oxazonecin in the transplant strategy for relapsed/refractory ALL. Speaker: Kenichi Matsuoka Chair: Noriko Doki (Pfizer Japan Inc.)		14:40~15:52 Oral Session 13 Early complications: Others 2 Hiroto Ishii p.40		16:25~17:15 SS8 Brentuximab vedotin for the treatment of patients with PTCLs Speaker: Shinichi Makita Chair: Kunihiko Tsukasaka (Takeda Pharmaceutical Company Limited)						
	Room 11 5F G510		9:45~10:57 Oral Session 14 cGVHD 1 Takuya Miyazaki p.41		11:20~12:10 LS10 Infectious disease management and vaccine strategies for post-allogeneic transplant patients Speaker: Yuki Asano-Mori Chair: Masahiro Hirayama (GlaxoSmithKline K.K.)		14:30~15:54 Oral Session 16 Management and care Mitsuru Itoh p.44		16:25~17:15 SS9 Transplant positioning in B-ALL treatment strategy Speaker: Koji Sasaki Chair: Naoto Takahashi (Amgen K.K./Astellas Pharma Inc.)						
	Room 12 6F G602	9:00~10:00 Oral Session 17 Transplant outcomes: AML 1 Masatsugu Tanaka p.45	10:05~11:05 Oral Session 18 Transplant outcomes: AML 2 Junichi Kitagawa p.46		11:20~12:10 LS11 Evidence and experience in the management of infectious diseases associated with hypogammaglobulinemia Speakers: Mitsutaka Nishimoto, Myraki Nishiura Chair: Kensuke Ohta (CSL Behring K.K.)		14:10~14:58 Oral Session 20 Transplant outcomes: MPN/MDS 1 Shokichi Tsukamoto p.48	15:10~15:58 Oral Session 21 Transplant outcomes: MPN/MDS 2 Yuta Katayama p.49	16:25~17:15 SS10 Roll of Monabli in autologous peripheral blood stem cell collection Speakers: Asuka Yamada, Junya Kanda Chair: Nobuhiko Tsukada (Sanofi K.K.)						
	Room 13 6F G610	9:00~10:00 Oral Session 22 Infections: CMV Hirozumi Sano p.50	10:10~10:58 Oral Session 23 Transplant outcomes: Elderly Yoshitaka Inoue p.51		11:20~12:10 LS12 Treatment Strategies for Relapsed and Refractory Peripheral T-Cell Lymphoma Speaker: Junichi Sugita Chair: Atsushi Wake (Meiji Seika Pharma Co., Ltd.)		14:05~15:05 Oral Session 25 TDM/drug-related Tetsuya Eto p.53	15:15~16:03 Oral Session 26 Infections: COVID-19 Shinsuke Kusakabe p.54	16:25~17:15 SS11 E License to Drive: Drifting through the curves of CAR-T therapy in Large B-cell Lymphoma Speaker: Matthew A. Luning Chair: Koji Izutsu (Bristol-Myers Squibb K.K.)						
	Room 14 7F G701	9:00~9:48 Oral Session 27 Supportive care Kazuko Ino p.55	10:00~11:00 Oral Session 28 Conditioning 1 Takahiro Fukuda p.56		11:20~12:10 LS13 The roles of Sarclisa in the 2nd line therapy of multiple myeloma Speakers: Motoko Shibata, Kazuhito Suzuki Chair: Tadao Ishida (Sanofi K.K.)		14:00~14:48 Oral Session 30 Transplant outcomes: Others Yoshihiro Umezawa p.58	15:00~16:00 Oral Session 31 Late complications: LTFU Yuki Asano-Mori p.59	16:25~17:15 SS12 Management of fungal infections in patients with hematologic diseases Speaker: Yasuo Mori Chair: Yuki Asano-Mori (Sumitomo Pharma Co., Ltd.)						
Poster	9:00~11:00		11:00~17:25						17:25~18:10 Poster Presentation P.93						
B2F															
Exhibition			10:00~18:15												
B2F															

Poster Presentation

- P-001 Stem Cell Biology
- P-002~P-008 Stem Cell Mobilization and Harvest
- P-009~P-014 Conditioning Regimens
- P-015~P-019 Transplant Immunity
- P-020~P-029 Immunotherapy / Cell therapy / Gene therapy
- P-030~P-033 Child-specific Transplant Disease
- P-034~P-055 Transplant Outcomes
- P-056~P-060 MRD and Relapse
- P-061~P-072 Early Complications
- P-073~P-085 Late Complications
- P-086~P-097 Infection
- P-098~P-101 LTFU and Team medical care
- P-102~P-104 Narrow Donor Program / Cord Blood Bank / Donors
- P-105~P-107 HCTC and Coordination
- P-108~P-109 Rehabilitation
- P-110~P-111 TDM / Drugs

Nursing Poster Presentation

- 看 P-01~看 P-10 Nursing / Education
- 看 P-11~看 P-16 Team Medical-care
- 看 P-17~看 P-22 Care
- 看 P-23~看 P-26 Follow-up and QOL